SAR288 has emerged as a potential therapeutic target for COVID-19. This pharmaceutical agent exhibits significant antiviral effects against SARS-CoV-2, the virus responsible for COVID-19. Preclinical studies have demonstrated that SAR288 can effectively block viral replication in vitro and in vivo. Furthermore, SAR288 has shown encouraging safety